eli lilly clinical trials tirzepatide gets a big win in obesity-related heart failure Eli Lilly launched a four-dose,

Peroxisome proliferator-activated receptor (PPAR)- activation prevents diabetes in OLETF rats: comparison with PPAR- activation

Multiple-dose pharmacokinetics and bioequivalence of L-carnitine 330mg tablet versus 1g chewable tablet versus enterai solution in healthy adult male volunteers

Importantly, the primary therapeutic goal in managing pediatric obesity extends beyond absolute weight reduction to encompass the mitigation of long-term cardiometabolic risk

By leveraging GLP-1 agonists before surgery, patients can get closer to their ideal weight, ultimately complementing the surgical outcomes and enhancing satisfaction with their appearance after surgery